GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)
India · Delayed Price · Currency is INR 2,600.00
-1.00 (-0.04%)
Aug 11, 2026, 3:29 PM IST
NSE:GLAXO Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 10,360 | 9,276 | 5,900 | 6,107 | 16,947 |
Depreciation & Amortization | 596.69 | 565.7 | 591.43 | 560.73 | 587.16 |
Other Amortization | 67.75 | 102.22 | 105.37 | 96.94 | 94.7 |
Loss (Gain) From Sale of Assets | 0.46 | 15.13 | -8.89 | -0.28 | -3.24 |
Loss (Gain) From Sale of Investments | -796.3 | -696.5 | -487.76 | -307.79 | -5.92 |
Provision & Write-off of Bad Debts | 18.86 | 23.76 | 5.87 | -73.64 | 1.62 |
Other Operating Activities | -232.61 | 1,765 | -895.67 | -1,124 | -11,442 |
Change in Accounts Receivable | 175.52 | -728.68 | -302.69 | 202.28 | 102.04 |
Change in Inventory | 241.82 | 433.11 | -650.78 | 747.25 | 120.03 |
Change in Accounts Payable | -1,389 | 769.69 | 1,901 | -1,532 | 1,024 |
Change in Other Net Operating Assets | -10.45 | 1,374 | -337.69 | 125.16 | -47.1 |
Operating Cash Flow | 9,033 | 12,899 | 5,820 | 4,842 | 8,107 |
Operating Cash Flow Growth | -29.97% | 121.63% | 20.20% | -40.27% | 40.29% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -552.79 | -230.22 | -312.22 | -440.39 | -346.41 |
Sale of Property, Plant & Equipment | 220.35 | 57.17 | 224.56 | 14.57 | 11.77 |
Sale (Purchase) of Real Estate | - | - | - | 97.8 | 323.42 |
Investment in Securities | 3,172 | -1,444 | -1,454 | 9,563 | -18,124 |
Other Investing Activities | 1,131 | 1,159 | 1,629 | -1,156 | 14,080 |
Investing Cash Flow | 3,970 | -458.01 | 87.12 | 8,079 | -4,055 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Long-Term Debt Repaid | -203.74 | -187.31 | -181.25 | -168.68 | -156.18 |
Net Debt Issued (Repaid) | -203.74 | -187.31 | -181.25 | -168.68 | -156.18 |
Common Dividends Paid | -7,140 | -7,494 | -5,416 | -15,255 | -5,066 |
Other Financing Activities | -27.32 | -13.14 | -17.99 | -9.55 | -19.9 |
Financing Cash Flow | -7,371 | -7,694 | -5,615 | -15,433 | -5,242 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash Flow | 5,632 | 4,747 | 292.3 | -2,512 | -1,190 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 8,480 | 12,669 | 5,508 | 4,402 | 7,761 |
Free Cash Flow Growth | -33.06% | 130.01% | 25.13% | -43.28% | 45.42% |
Free Cash Flow Margin | 22.19% | 33.79% | 15.95% | 13.54% | 23.68% |
Free Cash Flow Per Share | 50.06 | 74.78 | 32.51 | 25.98 | 45.81 |
Levered Free Cash Flow | 7,293 | 11,624 | 6,701 | 1,562 | 10,097 |
Unlevered Free Cash Flow | 7,310 | 11,632 | 6,712 | 1,573 | 10,109 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 27.32 | 13.14 | 17.99 | 13.98 | 17.37 |
Cash Income Tax Paid | 3,216 | 823.79 | 2,349 | 2,646 | 1,195 |
Change in Working Capital | -981.67 | 1,848 | 610.21 | -457.46 | 1,199 |